





Rapamycin (also called sirolimus) is an immuno-
suppressive drug that has recently been shown to extend 
lifespan in multiple species including mammals [1].   
This anti-aging property is presumably related to the 
mTOR (mammalian target of rapamycin) inhibition 
properties of rapamycin.  The mTOR pathway is crucial 
for the coordination of growth in response to energy 
status, stress, and nutrient availability [2,3].   
 
The potential anti-aging properties of rapamycin and of 
other mTOR inhibitors, such as RAD001 (everolimus), 
and CCI-779 (temsirolimus) are of great interest.   
Unfortunately, the side effects related to these drugs 
preclude the undertaking of research trials about their 
impacts on aging in healthy individuals. Considering 
this obstacle, experts in the field of aging have 
suggested that the potential anti-aging drugs should be 
introduced to the clinical trials for therapy of particular 
diseases and then be approved for prevention of all       
age-related diseases in healthy individuals [4]. In this 
context, tuberous sclerosis complex (TSC) seems to be 
an ideal disease model where the potential of mTOR 
inhibitors  can  be  assessed   because   these  drugs   are 
 
 






























increasingly being tested and used clinically to treat 
certain aspects of this condition [5].   
 
TSC is an autosomal dominant disorder caused by the 
inactivation in one of two tumor suppressor genes, 
hamartin (TSC1) or tuberin (TSC2). In the normal state, 
the hamartin–tuberin complex activates the protein 
Rheb, which inhibits mTOR.  If a TSC mutation is 
present, mTOR is constitutively activated, leading to 
abnormal cellular proliferation, ribosome biogenesis, 
and mRNA translation (see [2] for complete review of 
the mTOR molecular pathway).  In consequence, TSC 
is characterized clinically by the growth of benign 
tumors in multiple organs, including the brain, the heart, 
the kidneys, the lungs, and the skin [6].  Its incidence is 
estimated at 1 in 6000 live births [7].  The severity of 
the disease is highly variable, ranging from mild skin 
manifestations to intractable epilepsy, mental retard-
ation, and autism [8].   
 
The only report studying specifically the causes of death 
in TSC was performed at the Mayo clinic [9]. Overall, 
the survival curves showed a decreased survival for 
Potential of mTOR inhibitors for the treatment of subependymal














Abstract:  Rapamycin  inhibits  the  mTOR  (target  of  rapamycin)  pathway  and  extends  lifespan  in  multiple  species.  The
tuberous sclerosis complex (TSC) protein is a negative regulator of mTOR. In humans, loss of the TSC protein results in a
disorder  characterized  clinically  by  the  growth  of  benign  tumors  in  multiple  organs,  due  to  overactivation  of  mTOR
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population.  Of the 355 patients with TSC followed, 40 
died of causes related to TSC, with renal disease being 
the most common cause of death (11/40). Ten patients 
died as a consequence of brain tumors and four patients 
died of lymphangioleiomyomatosis (LAM). Thirteen 
patients with severe mental impairment passed away 
due to status epilepticus or bronchopneumonia. One 
baby died of cardiac failure and one child died of 
rupture of an aneurysm of the thoracic aorta.   
 
The main current clinical complication related to TSC 
for which treatment with mTOR inhibitors is indicated 
are subependymal giant cell astrocytomas (SEGA).   
This complication affects approximately 15% of 
patients with TSC and it occurs in the pediatric age 
group [10]. SEGAs tend to lose their propensity to grow 
in the early twenties.  They are slow-growing benign 
tumors of mixed glioneuronal lineage that arise from the 
growth of pre-existing subependymal nodules, which 
are asymptomatic lesions that protrude from the walls of 
the ventricles [10].  SEGAs most commonly grow near 
the foramen of Monro. This can lead to obstruction of 
the normal cerebrospinal fluid circulation and sub-
sequent intracranial hypertension that can potential be 
fatal if left untreated.  The distinction between a SEGA 
and a subependymal nodule is still debated.  Generally, 
a clinical diagnosis of SEGA is made when there are 
symptoms of intracranial hypertension, papilledema, or 
radiological evidence of hydrocephalus or interval 
growth.   
 
The traditional management approach is to monitor 
SEGAs with periodic neuroimaging and to resect those 
that exhibit growth and/or cause clinical signs of 
intracranial hypertension. This approach is being 
challenged by recent observations that suggest that 
mTOR inhibitors, such as rapamycin (sirolimus) and 
RAD001 (everolimus), can induce partial regression of 
SEGAs [11,12,13]. The first report showing clear 
regression of SEGAs in five patients with the use of 
rapamycin was published in 2006 [11]. Recently, a 
phase II trial [13] using everolimus to treat SEGAs in 
28 patients with TSC showed SEGA reduction of at 
least 30% in 21 patients (75%) and at least 50% in 9 
patients (32%).  Everolimus was well tolerated as only 
single cases of grade 3 treatment-related sinusitis, 
pneumonia, viral bronchitis, tooth infection, stomatitis, 
and leukopenia were reported.   
 
These observations suggest that mTOR inhibitors could 
serve as an acceptable alternative treatment to SEGA 
surgery. Renal angiomyolipomas and lymphangio-
leimyomatosis (LAM) are other TSC manifestations for 
which mTOR inhibitors have proven potential efficacy 
[14]. In addition, animal models of TSC have suggested 
that mTOR inhibitors could have beneficial effects on 
cognitive deficits [15] and on epileptogenesis [16]. 
Whether similar benefits would be observed in humans 
with TSC is still unknown.  Research trials are ongoing 
and should soon provide answers to these questions.   
 
Other important questions remain regarding the use of 
mTOR inhibitors for the treatment of SEGA in TSC.   
Side effects, especially long term side effects, and 
optimal duration of treatment are still under investigation. 
The short-term side effects related to rapamycin are 
generally considered acceptable. The most common side 
effects are oral ulcers, acneiform rash, thrombocytopenia, 
hyperlipidemia, impaired wound healing, and immuno-
suppression [14]. Long term side effects are less known.  
For example, reports from the literature related to the use 
of rapamycin for kidney transplant prevention suggested 
that rapamycin might be associated with impaired 
spermatogenesis and, as a corollary, may reduce male 
fertility [17].  This observation might not be applicable   
to other patients populations, but requires further invest-
igation.   
 
The duration of treatment might be prolonged, probably 
lifelong. There is clear evidence that SEGAs grow back 
after the mTOR inhibitor is stopped [11].  Most experts 
currently recommend continuation of mTOR inhibitors 
at the lowest efficacious dose. This cohort of patients 
who will experience prolonged exposure to mTOR 
inhibitors should be carefully followed longitudinally to 
better document long term side effects, but also to 
compare their longevity with the one of similar patients 
with TSC. These patients represent a unique opportunity 
to study the potential anti-aging properties of mTOR 
inhibitors in humans. 
 
In conclusion, a new treatment era has begun in the 
field of TSC since the discovery of the potential 
beneficial effects of mTOR inhibitors. Although the 
use of mTOR inhibitors is becoming increasingly 
accepted, especially for the treatment of SEGAs in 
TSC, questions now remain about the duration of 
treatment and long term side effects. Whether mTOR 
inhibitors will have a significant impact on longevity 
in TSC is unknown, but warrants attention as mTOR 
inhibitors are increasingly recognized as anti-aging 
drugs in animal models. Long-term prospective studies 
in patients with TSC might provide evidence about the 
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